Please use this identifier to cite or link to this item: http://scholarbank.nus.edu.sg/handle/10635/117137
Title: Rapid determination of gemcitabine and its metabolite in human plasma by LC-MSMS through micro protein precipitation with minimum matrix effect
Authors: Wang, L.-Z. 
Yong, W.-P. 
Soo, R.-A. 
Lee, S.-C. 
Soong, R. 
Lee, H.-S.
Goh, B.-C.
Keywords: 2′
2′-difluorodeoxyuridine
Gemcitabine
Human plasma
LC-MSMS
Issue Date: 2009
Citation: Wang, L.-Z.,Yong, W.-P.,Soo, R.-A.,Lee, S.-C.,Soong, R.,Lee, H.-S.,Goh, B.-C. (2009). Rapid determination of gemcitabine and its metabolite in human plasma by LC-MSMS through micro protein precipitation with minimum matrix effect. Journal of Pharmaceutical Sciences and Research 1 (3) : 23-32. ScholarBank@NUS Repository.
Abstract: A novel micro protein precipitation was proposed and employed effectively for bio-sample preparation of only 5 μl of human plasma for rapid liquid chromatography- tandem mass spectrometric (LC-MSMS) determination of gemcitabine (dFdC) and its deaminated metabolite, 2′, 2′-difluorodeoxyuridine (dFdU).). Gemcitabine-13C, 15N2 Hydrochloride was the internal standard. Baseline chromatographic separation was achieved with an Alltima C 18 column (2.1×100 mm, 5μm) using isocratic mobile phase [10 mM ammonium acetate (pH = 6.8): methanol, 90:10]. The run time was only 5 min. The mass spectrometer was operated under a positive electrospray ionization condition and a multiple reaction monitoring mode. The linear calibration ranges were 2-2,000 ng/ml for gemcitabine and 20-20,000 ng/ml for dFdU. The recoveries for three analytes were in the same magnitude range from 87.7 to 89.7% with small variation. The intra and inter-day precisions for dFdC and dFdU were ≤ 5 and ≤ 7 and their accuracy ranged from 98 to 105.3% for dFdC and 93.8 to 104.9% for dFdU, respectively. Ion suppression effect was near negligible. This well validated assay has been applied for quantification of gemcitabine and dFdU in our gemcitabine phase II clinical trial study on Asian non-small cell lung cancer patients treated with different infusional rates of gemcitabine.
Source Title: Journal of Pharmaceutical Sciences and Research
URI: http://scholarbank.nus.edu.sg/handle/10635/117137
ISSN: 09751459
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

Page view(s)

48
checked on Sep 28, 2018

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.